X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8397) 8397
taxoids - administration & dosage (5744) 5744
female (5623) 5623
oncology (5035) 5035
middle aged (4802) 4802
antineoplastic combined chemotherapy protocols - therapeutic use (4639) 4639
aged (4355) 4355
docetaxel (4175) 4175
male (4127) 4127
adult (3485) 3485
chemotherapy (3404) 3404
treatment outcome (2566) 2566
cancer (2483) 2483
breast neoplasms - drug therapy (2445) 2445
antineoplastic combined chemotherapy protocols - adverse effects (1850) 1850
taxoids - therapeutic use (1768) 1768
taxoids - adverse effects (1712) 1712
paclitaxel (1659) 1659
cisplatin - administration & dosage (1551) 1551
paclitaxel - administration & dosage (1500) 1500
breast neoplasms - pathology (1421) 1421
drug administration schedule (1410) 1410
breast cancer (1391) 1391
taxoids (1356) 1356
neoplasm staging (1328) 1328
lung neoplasms - drug therapy (1308) 1308
disease-free survival (1226) 1226
antineoplastic agents - administration & dosage (1190) 1190
aged, 80 and over (1188) 1188
pharmacology & pharmacy (1174) 1174
animals (1172) 1172
fluorouracil - administration & dosage (1160) 1160
paclitaxel - analogs & derivatives (1121) 1121
antineoplastic combined chemotherapy protocols - administration & dosage (1114) 1114
cisplatin (1114) 1114
deoxycytidine - analogs & derivatives (1093) 1093
care and treatment (1075) 1075
carcinoma, non-small-cell lung - drug therapy (1068) 1068
antineoplastic agents - therapeutic use (1053) 1053
therapy (1042) 1042
trial (1012) 1012
medicine & public health (983) 983
deoxycytidine - administration & dosage (976) 976
survival rate (935) 935
retrospective studies (872) 872
prognosis (869) 869
survival analysis (852) 852
survival (832) 832
neoplasm metastasis (808) 808
cell line, tumor (804) 804
prostatic neoplasms - drug therapy (803) 803
prostate cancer (789) 789
research (789) 789
chemotherapy, adjuvant (787) 787
metastasis (768) 768
mice (766) 766
dose-response relationship, drug (763) 763
carcinoma (749) 749
antineoplastic agents, phytogenic - administration & dosage (729) 729
antineoplastic agents (727) 727
taxoids - pharmacology (722) 722
neoadjuvant therapy (693) 693
hematology, oncology and palliative medicine (692) 692
analysis (664) 664
combined modality therapy (663) 663
antimitotic agents (658) 658
doxorubicin (657) 657
lung neoplasms - pathology (652) 652
combination (622) 622
cyclophosphamide - administration & dosage (618) 618
drug therapy (612) 612
adenocarcinoma - drug therapy (607) 607
carboplatin - administration & dosage (599) 599
doxorubicin - administration & dosage (599) 599
drug resistance, neoplasm (594) 594
antineoplastic agents - adverse effects (593) 593
antineoplastic agents, phytogenic - therapeutic use (579) 579
stomach neoplasms - drug therapy (569) 569
paclitaxel - adverse effects (564) 564
follow-up studies (561) 561
phase-ii trial (559) 559
taxoids - pharmacokinetics (547) 547
gemcitabine (536) 536
disease progression (534) 534
carcinoma, non-small-cell lung - pathology (525) 525
cancer research (508) 508
clinical trials (504) 504
tumors (490) 490
capecitabine (489) 489
kaplan-meier estimate (489) 489
prospective studies (488) 488
carcinoma, squamous cell - drug therapy (483) 483
phase-ii (482) 482
fluorouracil (480) 480
trastuzumab (479) 479
neutropenia - chemically induced (473) 473
paclitaxel - therapeutic use (469) 469
carboplatin (461) 461
neoplasms - drug therapy (453) 453
radiotherapy (448) 448
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8138) 8138
Japanese (543) 543
Chinese (120) 120
French (84) 84
German (69) 69
Russian (35) 35
Italian (27) 27
Spanish (18) 18
Hungarian (15) 15
Portuguese (5) 5
Lithuanian (4) 4
Czech (3) 3
Dutch (2) 2
Finnish (2) 2
Korean (2) 2
Croatian (1) 1
Danish (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
.... We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop... 
Camptothecin | Stomach | Anthracyclines | Gastroenterology & hepatology | Cancer: other gastrointestinal | Palliation | Docetaxel | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Randomized Controlled Trials as Topic | Irinotecan | Chemotherapy | Treatment | Taxoids | Stomach Neoplasms | Medicine General & Introductory Medical Sciences | Fluorouracil | Cancer | 1ST-LINE TREATMENT | OLDER-ADULT PATIENTS | COLONY-STIMULATING FACTOR | Humans | Anthracyclines [administration & dosage] | Cisplatin [administration & dosage] | HIGH-DOSE 5-FLUOROURACIL | Fluorouracil [administration & dosage] | MEDICINE, GENERAL & INTERNAL | analogs & derivatives | RANDOMIZED PHASE-II | ADVANCED GASTROINTESTINAL CANCER | mortality | Taxoids [administration & dosage] | Antineoplastic Combined Chemotherapy Protocols [therapeutic use] | QUALITY-OF-LIFE | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Camptothecin [administration & dosage | Stomach Neoplasms [drug therapy | S-1 PLUS CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Stomach Neoplasms - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 7, pp. 860 - 867
Journal Article